蛋白

PI3K(p85甲)重组蛋白

MBS515195

0.02毫克

270美元

重组蛋白

PI3K(p85甲)重组蛋白

[PI3K(p85甲)]

[PI3K催化域甲;磷酸肌醇3激酶调节亚单位1;GRB1;p85-甲;PI3K(p85alpha)蛋白;PI3K(p85a)蛋白]

[Homo sapiens phosphoinositide-3-kinase, regulatory subunit 1 (alpha) (PIK3R1), transcript variant 1, mRNA; Phosphatidylinositol 3-kinase regulatory subunit alpha; phosphatidylinositol 3-kinase regulatory subunit alpha; PI3-kinase subunit p85-alpha; PI3K regulatory subunit alpha; ptdIns-3-kinase regulatory subunit alpha; phosphoinositide-3-kinase regulatory subunit; phosphatidylinositol 3-kinase-associated p-85 alpha; phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha; phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha); phosphoinositide-3-kinase, regulatory subunit 1 (alpha); Phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha]

[PI3K(p85甲)]

[磷酸肌醇3激酶调节亚单位1;GRB1;p85-甲]

[PIK3R1; PIK3R1; p85; AGM7; GRB1; p85-ALPHA; GRB1; PI3-kinase regulatory subunit alpha; PI3K regulatory subunit alpha; PtdIns-3-kinase regulatory subunit alpha; PI3-kinase subunit p85-alpha]

P85A_HUMAN

Sf9昆虫细胞

>95%

Recombinant protein stored in 50mM Sodium phosphate, pH 7.0, 300 mM NaCl, 150 mM imidazole, 0.1mM PMSF, 0.25 mM DTT, 25% Glycerol.

0.2微克/微升

Store product at -70°C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles. Ships with dry ice.

Kinase Assay, Western Blot (WB)

十二烷基磺酸钠-PAGE

Cellular Proteins; Signaling Proteins - Cellular Proteins

Recombinant full-length human PI3K (p85alpha) was expressed by baculovirus in Sf9 insect cells using an N-terminal His tag. Scientific Background: The PI3K comprises of a 110 kDa catalytic subunit and a 85 kDa regulatory subunit. A number of isoforms of the 110 kDa catalytic subunit and the 85 kDa regulatory subunit exist in cells. p85alpha modulates the interaction between PI3K and platelet-derived growth factor receptor (1). Furthermore, estrogen receptor isoform ER-alpha binds in a ligand-dependent manner to the p85-alpha regulatory subunit of PI3K. Stimulation with estrogen increases ER-alpha-associated PI3K activity, leading to the activation of protein kinase B/AKT and endothelial nitric oxide synthase (eNOS) (2).

1. Skolnik, E. Y. Et al: Cloning of PI3-kinase associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases. Cell 65: 83-90, 1991. 2. Simoncini, T. et al: Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407: 538-541, 2000.

335057530

NP_852664.1

NM_181523

P27986

3-phosphoinositide Biosynthesis Pathway (545314); 3-phosphoinositide Biosynthesis Pathway (138600); AMPK Signaling Pathway (198868); Acute Myeloid Leukemia Pathway (83117); Acute Myeloid Leukemia Pathway (529); Adaptive Immune System Pathway (366160); Aldosterone-regulated Sodium Reabsorption Pathway (130626); Aldosterone-regulated Sodium Reabsorption Pathway (130590); Alpha6-Beta4 Integrin Signaling Pathway (198807); Amoebiasis Pathway (167324)

Phosphatidylinositol 3-kinase phosphorylates the inositol ring of phosphatidylinositol at the 3-prime position. The enzyme comprises a 110 kD catalytic subunit and a regulatory subunit of either 85, 55, or 50 kD. This gene encodes the 85 kD regulatory subunit. Phosphatidylinositol 3-kinase plays an important role in the metabolic actions of insulin, and a mutation in this gene has been associated with insulin resistance. Alternative splicing of this gene results in four transcript variants encoding different isoforms. [provided by RefSeq, Jun 2011]

Function: Binds to activated (phosphorylated) protein-Tyr kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues. Plays an important role in signaling in response to FGFR1, FGFR2, FGFR3, FGFR4, KITLG/SCF, KIT, PDGFRA and PDGFRB. Likewise, plays a role in ITGB2 signaling. Ref.11 Ref.50 Ref.52. Subunit structure: Heterodimer of a regulatory subunit PIK3R1 and a p110 catalytic subunit (PIK3CA, PIK3CB or PIK3CD). Interacts with FER. Interacts (via SH2 domain) with TEK/TIE2 (tyrosine phosphorylated). Interacts with PTK2/FAK1 . By similarity. Interacts with phosphorylated TOM1L1. Interacts with phosphorylated LIME1 upon TCR and/or BCR activation. Interacts with SOCS7. Interacts with RUFY3. Interacts (via SH2 domain) with CSF1R (tyrosine phosphorylated). Interacts with LYN (via SH3 domain); this enhances enzyme activity . By similarity. Interacts with phosphorylated LAT, LAX1 and TRAT1 upon TCR activation. Interacts with CBLB. Interacts with HIV-1 Nef to activate the Nef associated p21-activated kinase (PAK). This interaction depends on the C-terminus of both proteins and leads to increased production of HIV. Interacts with HCV NS5A. The SH2 domains interact with the YTHM motif of phosphorylated INSR in vitro. Also interacts with tyrosine-phosphorylated IGF1R in vitro. Interacts with CD28 and CD3Z upon T-cell activation. Interacts with IRS1 and phosphorylated IRS4, as well as with NISCH and HCST. Interacts with FASLG, KIT and BCR. Interacts with AXL, FGFR1, FGFR2, FGFR3 and FGFR4 (phosphorylated). Interacts with FGR and HCK. Interacts with PDGFRA (tyrosine phosphorylated) and PDGFRB (tyrosine phosphorylated). Interacts with ERBB4 (phosphorylated). Interacts with NTRK1 (phosphorylated upon ligand-binding). Ref.2 Ref.9 Ref.10 Ref.12 Ref.13 Ref.14 Ref.15 Ref.16 Ref.17 Ref.18 Ref.19 Ref.20 Ref.21 Ref.22 Ref.23 Ref.24 Ref.25 Ref.26 Ref.27 Ref.28 Ref.29 Ref.30 Ref.32 Ref.36 Ref.37 Ref.38 Ref.52. Tissue specificity: Isoform 2 is expressed in skeletal muscle and brain, and at lower levels in kidney and cardiac muscle. Isoform 2 and isoform 4 are present in skeletal muscle (at protein level). Ref.2. Domain: The SH3 domain mediates the binding to CBLB, and to HIV-1 Nef. Post-translational modification: Polyubiquitinated in T-cells by CBLB; which does not promote proteasomal degradation but impairs association with CD28 and CD3Z upon T-cell activation.Phosphorylated. Tyrosine phosphorylated in response to signaling by FGFR1, FGFR2, FGFR3 and FGFR4. Phosphorylated by CSF1R. Phosphorylated by ERBB4. Phosphorylated on tyrosine residues by TEK/TIE2. Dephosphorylated by PTPRJ. Phosphorylated by PIK3CA at Ser-608; phosphorylation is stimulated by insulin and PDGF. The relevance of phosphorylation by PIK3CA is however unclear . By similarity. Phosphorylated in response to KIT and KITLG/SCF. Phosphorylated by FGR. Ref.33 Ref.35. Involvement in disease: Agammaglobulinemia 7, autosomal recessive (AGM7) [MIM:615214]: A primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B cells due to an early block of B-cell development. Affected individuals develop severe infections in the first years of life.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.42. Sequence similarities: Belongs to the PI3K p85 subunit family.Contains 1 Rho-GAP domain.Contains 2 SH2 domains.Contains 1 SH3 domain.

0.02毫克

270美元

0.05毫克

450